CN Search Menu
Home|News

2024/01/05

Shandong Xinbo Pharmaceutical Research Co., Ltd. held the 2nd Anatomy Skills Competition

...
More
我司高级副总经理刘宝峰荣获2023年度德州市企业“创新达人”称号

2023/11/24

Our Senior Vice General Manager Liu Baofeng has been awarded the title of "Innovation Expert" for enterprises in Dezhou City in 2023

...
山东欣博完成iNKT细胞产品GKL-006注射液非临床研究，助力获临床试验许可

2023/11/24

Shandong Xinbo completes non clinical research on iNKT cell product GKL-006 injection, helping to obtain clinical trial approval

Shandong Xinbo supports the clinical approval of the first iNKT cell product targeting liver cancer in China...
山东欣博完成全人源抗破伤风毒素单克隆抗体A82/B86注射液组合制剂非临床研究，助力获临床试验批准

2023/11/11

Shandong Xinbo has completed a non clinical study on the combination of human monoclonal antibodies A82/B86 for tetanus toxin injection, helping to obtain clinical trial approval

On October 30, 2023, Changchun Baike Biotechnology Co., Ltd...
山东欣博助力PLpro小分子抑制剂获批临床

2023/09/22

Shandong Xinbo supports the approval of the world's first PLpro small molecule inhibitor for clinical use

On August 29, 2023, a team led by He Wei from the School of Pharmacy at Tsinghua University, in collaboration with the Land Transport Team from the School of Basic Medicine at Fudan University, conducted research and development...
山东欣博助力肠道病毒71型-柯萨奇病毒A16型灭活疫苗(人二倍体细胞)获批开展临床

2023/09/22

Shandong Xinbo supports the approval of clinical trials for the inactivated vaccine of enterovirus 71 Coxsackievirus A16 (human diploid cell)

In September 2023, the Institute of Medical Biology, Chinese Academy of Medical Sciences independently developed an enterovirus...
山东欣博获得第二届医疗器械植入后反应实验室间比对活动“满意”证书

2023/06/13

Shandong Xinbo received the "Satisfaction" certificate for the second inter laboratory comparison activity of post implantation reactions of medical devices

On June 9, 2023, Shandong Xinbo Pharmaceutical Research Co., Ltd. (hereinafter referred to as "Shandong Xinbo") participated in the second inter laboratory comparison activity for post implantation reactions of medical devices....
山东欣博完成NMM肿瘤治疗性DNA疫苗裸质粒注射液非临床研究，助力获临床试验许可

2023/04/07

Shandong Xinbo completes non clinical research on NMM tumor therapeutic DNA vaccine naked plasmid injection, helping to obtain clinical trial approval

Recently, Gu'an Dingtai Haigui Biotechnology Co., Ltd. developed a Class 1 new drug - the NMM tumor therapeutic DNA vaccine naked plasmid injection...
山东欣博药物研究有限公司入选“2023年TOP10最具潜力CGT CRO”榜单

2023/03/28

Shandong Xinbo Pharmaceutical Research Co., Ltd. has been selected as one of the "Top 10 Most Promising CGT CROs of 2023"

Shandong Xinbo Pharmaceutical Research Co., Ltd. has been selected as one of the "Top 10 Most Promising CGT CROs of 2023"...
山东欣博完成天然全人源抗狂犬病毒单克隆抗体CBB1注射液非临床研究，助力获临床试验许可

2023/03/15

Shandong Xinbo has completed the non clinical study of natural human monoclonal antibody CBB1 injection against rabies virus, helping to obtain clinical trial approval

Recently, Changchun Baike Biotechnology Co., Ltd.'s Class 1 new drug - natural all human monoclonal antibody CBB1 injection against rabies virus - has been approved by the National Medical Products Administration (NMPA) of China....
上一页 12345678 下一页

您是否找到了需要的信息？

太好了，感谢您提供反馈。
感谢您提供反馈。